
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some red flags related to prescriptions that can lead to administrative action from the DEA.
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some red flags related to prescriptions that can lead to administrative action from the DEA.
This video was recorded at the 2015 NCPA Annual Convention.






